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PCN188
SubCutaNeouS VS INtraVeNouS admINIStratIoN of traStuzumab IN 
Her2+ breaSt CaNCer PatIeNtS: a maCedoNIaN CoSt-mINImIzatIoN 
aNalySIS
Nestorovska A1, Naumoska Z1, Grozdanova A1, Stoleski D2, Ivanovska A2, Risteski M3, 
Vasev N3, Ismaili I3, Stefanovski P4, Dimovski A1, Suturkova L1, Sterjev Z5
1ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia, 2Roche Macedonia, DOOEL, 
Skopje, Macedonia, 3University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, 4Clinical 
Hospital, Bitola, Macedonia, 5Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia
Objectives: The aim of this study is to compare the total cost of subcutaneous 
trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer 
patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharma-
cokinetic profile and efficacy non-inferior to standard IV-TRA and is a valid alternative 
for the treatment of eligible breast cancer patients. MethOds: A cost-minimization 
analysis was performed using data from prior prospective time-motion study. Total 
time and cost of both types of TRA administration were quantified in a time horizon 
of over 18 cycles therapy course.The total of 169 patients (mean weight 74.20 kg) (300 
observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and 
received the drug in the adjuvant (132 patients) or first line metastatic (37 patients) 
setting. Health care resources included drug treatment, patient’s room and chair time 
treatments, active healthcare professional time and consumables. Non-health care 
resources encompassed patients’ transport. The model accounted the 3%wastage of 
IV-TRA administration. Unit costs were obtained utilizing official (government and 
hospital pharmacy) publicly available data and they were expressed in Euro 2015, with 
no discount. Results: Direct medical costs per (mean weight) patient were € 30 500 
for IV-TRA and € 30 102 for SC-TRA. The mean total costs per patient of IV compared 
to SC administratuin of TRA over the full course of treatment were € 30 695 and € 30 
106, respectively. SC-TRA incurred less non-drug related cost (€ 4,20) than IV-TRA 
(€ 196). The results of the model were most sensitive to patient weight and % of wast-
age in IV treated patients. Mean cost saving per patient over a full treatment course 
for SC administration was € 589,2. Mean savings (preparation and administration) in 
time with SC-TRA were 47 min. cOnclusiOns: SC-TRA can be time and cost-saving 
therapy for HER2+ breast cancer patients from the R. Macedonia.
PCN189
PHarmaCoeCoNomIC eValuatIoN of tHe uSe of traStuzumab for 
SubCutaNeouS admINIStratIoN ComPared to INtraVeNouS doSage 
form IN tHe treatmeNt of breaSt CaNCer
Kulikov A, Rybchenko Y
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To determine the preferable treatment scheme for breast cancer (BC) 
from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) 
and intravenous (IV) administration. MethOds: The following pharmacoeconomic 
methods were used: cost-minimization analysis, budget impact analysis. Results: 
For cost-minimization analysis the following costs were included: cost of testing on 
tumor expression of HER2, the main drug therapy, concomitant therapy (medical 
services and drugs), introduction, services provided by medical personnel and the 
conditions of administration (in case of hospitalization or outpatient). Total costs per 
1 patient with BC for treatment course with trastuzumab for subcutaneous admin-
istration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastu-
zumab for IV administration. Cost-minimization analysis revealed treatment change 
from trastuzumab for IV administration on trastuzumab for SC administration gave 
economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According 
to budget impact analysis it was revealed that trastuzumab for SC administration 
allows to make economy of 175 508 955 RUB/2 919 796 EUR. cOnclusiOns: During 
cost-minimization analysis it is determined that trastuzumab for IV allows to obtain 
economy compared with IV dosage form. Budget impact analysis reveals that change 
of BC treatment from trastuzumab for IV administration on trastuzumab for SC one 
give monetary economy.
PCN190
PHarmaCoeCoNomIC Study of tHe uSe of rItuxImab for SubCutaNeouS 
admINIStratIoN IN tHe treatmeNt of follICular lymPHoma
Kulikov A, Rybchenko Y
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To determine the most preferable from the pharmacoeconomic per-
spective treatment scheme of follicular lymphoma (FL) treatment with rituximab for 
subcutaneous (SC) and intravenous (IV) administration. MethOds: For this objective, 
the following pharmacoeconomic methods were used: cost-minimization analysis, 
budget impact. Results: The following costs were calculated for cost-minimization 
analysis: the main drug therapy, concomitant therapy, including medical services 
and medicines, administration, services provided by medical personnel and the 
conditions of administration (outpatient or hospitalization). According to the cost 
analysis it was determined that cost of FL treatment equals 3 534 687 RUB/ 58 803 
EUR under IV administration and 3 498 840 RUB/58 207 EUR under SC one. Cost-
minimization analysis revealed that rituximab for SC administration compared with 
IV one gives economy of 35 847 RUB/ 596 EUR per one patient for treatment course. 
During budget impact analysis it was determined that rituximab for SC administra-
tion gives 177 083 678 RUB/ 2 945 994EUR economy for treatment course of all patients 
in Russia. cOnclusiOns: According to cost-minimization analysis, subcutaneous 
dosage form of rituximab allows to obtain economy compared with intravenous form. 
Budget impact analysis shows that rituximab for subcutaneous administration allows 
to make economy.
PCN191
CoSt-effeCtIVeNeSS aNalySIS of obINutuzumab for PreVIouSly 
uNtreated CHroNIC lymPHoCytIC leukemIa (Cll) IN PortugueSe 
PatIeNtS tHat are uNSuItable for full-doSe fludarabINe baSed 
tHeraPy
expected to prevent an even broader spectrum of HPV-related cancers and other 
diseases and in particular, 90% of cervical cancers. This objective of this study was to 
estimate the incremental public health impact of a girls-only vaccination program 
with that of a universal vaccination program with a nonavalent human papillo-
mavirus vaccine in Germany as compared to the current girls-only vaccination 
with a quadrivalent HPV vaccine (6/11/16/18). MethOds: A dynamic transmission 
model of HPV infection and the related diseases was calibrated to the German 
epidemiological data. Up to 70% of cervical cancer cases were attributed to HPV 
16/18 for the quadrivalent vaccine, and an additional 20% to the five additional 
types included in the nonavalent vaccine. In the base case, a two dose vaccination 
program with lifelong protection and a cumulative vaccination coverage rate of 
55.6% was assumed. Sensitivity analyses were conducted. Results: The findings 
of the analyses indicate that girls-only vaccination with the nonavalent vaccine 
has the potential to: i) reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 73% after 100 years, relative to 57% for the quadrivalent vaccine 
and , ii) prevent an additional of 345,627 cases of CIN2/3 and 25,566 cases of cervical 
cancer over 100 years. When vaccination of girls with the nonavalent vaccine was 
extended to boys, the cumulative reduction over 100 years in the incident cases 
was 498,007 and 39,489 of CIN2/3 and cervical cancer respectively. cOnclusiOns: 
The introduction of a nonavalent HPV vaccine immunization program in Germany 
is estimated to significantly reduce the public health impact of cervical and other 
HPV-related diseases.
PCN186
CoSt-effeCtIVeNeSS aNd feaSIbIlIty of ImPlemeNtINg mrI-guIded 
NeoadJuVaNt CHemotHeraPy to treat er-PoSItIVe Her2-NegatIVe 
breaSt CaNCerS IN tHe NetHerlaNdS
Miquel-Cases A1, Steuten L2, Rigter L1, van Harten WH1
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Washington and 
Panaxea bv, Seattle, WA, USA
Objectives: Evidence suggests that response-guided neoadjuvant chemotherapy 
(RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestro-
gen receptor positive/human epidermal growth factor receptor-2 negative (ER+/
HER2-) breast cancer patients. We estimated the expected cost-effectiveness and 
resource requirements of implementing RG-NACT with MRI vs. conventional-NACT 
for treatment of ER+/HER2- breast cancers in the Netherlands (NL). MethOds: A 
Markov-model was developed to analyse the incremental costs/QALY from a hos-
pital perspective over a 5-year time horizon. Health services required (MRI scans 
performed, MRI technologists, breast radiologists and confirmatory scans) for and 
health outcomes (prevented relapses, prevented deaths, patients with adverse 
events or contraindications and MRI technologists with adverse events) of imple-
menting RG-NACT were estimated via resource modelling analysis considering the 
current (4%) and a full implementation (100%) scenario in the Dutch population of 
ER+/HER2- breast cancer women (n= 6306). Results: RG-NACT is expected to gener-
ate 0.001 and 0.07 QALYs and save € 8 and € 341 costs for the 4% and 100% implemen-
tation scenarios respectively. At current implementation rate, 213 MRI examinations, 
273 MRI technologists and 1 breast radiologist are required to prevent 0.4 relapses 
and 6 cancer deaths. At full implementation, a 25-fold increase in MRI examina-
tions is projected, requiring ~5 times higher MRI utilization and 6560 additional MRI 
technologists, which is expected to prevent 10 additional relapses (+2400%) and 169 
cancer deaths (+2400%). Increasing implementation rates markedly increased the 
number of confirmatory scans (+901), contraindications (+932) and MRI technolo-
gists experiencing adverse events (+1706) by 25-fold, and decreased the number 
of patients with adverse events (-29) by 1.3-fold. cOnclusiOns: RG-NACT likely 
dominates conventional-NACT at current and full implementation rates. Full imple-
mentation generates a 25-fold increase in additional health benefits, but requires 
MRI capacity in the Netherlands to be increased 5-fold, which is challenging given 
a shortage of MRI technologists.
PCN187
eCoNomIC eValuatIoN of oral CHemotHeraPy regImeN IN metaStatIC 
breaSt CaNCer egyPtIoN ProSPeCtIVe
Abo Taleb AM1, Saad AS A2, Aboushady R3
1WHO, Cairo, Egypt, 2Ain Shams University, Cairo, Egypt, 3Central Administration for 
Pharmaceutical Affairs, cairo, Egypt
Objectives: The main objective for conducting this study was to evaluate economic 
evaluation through the cost-effectiveness study of oral chemotherapy regimens 
we choose vinorelbine oral capsule plus oral capecitabine versus docetaxel iv plus 
oral capecitabine in treatment of metastatic breast cancer, in the Egyptian patients 
previously treated with anthracycline, from the national fund perspective over a 
time horizon of 3 years. MethOds: A cost-effectiveness analysis from the perspec-
tive of the Ministry of Health and Population was conducted. A Markov model was 
applied with three health states. Utility data were incorporated in the model to make 
adjusted results. Costs used were the local ones according to the national fund list. 
Discounting was applied at 3.5% annually both on costs and benefits. The results 
obtained were in term of ICER and number of QALYs. Robustness of our findings 
was checked using sensitivity analyses. Results are expressed in QALYs Results: 
During the three-year time horizon, the total cost for oral chemotherapy regimen 
vinorelbine oral plus capsitabine was associated with a 2.46QALY gained. The total 
for docetaxel IV. was associated with 0.84 QALY gained.That yields a difference of 
and 1.62 in QALY. The oral chemotherapy regimen( Vinorelbine oral plus capsitabine 
is economically dominating the docetaxel strategy, producing more benefit at a 
lower cost. The one-dimensional sensitivity analysis indicated that the overall sur-
vival medians of both drugs had the largest impact on the results. When conducting 
sensitivity analysis using plausible ranges, Vinorelbine oral remained economically 
dominant in all cases. cOnclusiOns: The introduction of oral chemotherapy regi-
men in metastatic breast cancer vinorelbine oral to the national fund Pay-at-The-
Expense-of-the-State (PTES) system was likely be cost saving based strictly from 
its perspective.
A464  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
ment of patients with MPC as it delivers a survival advantage at a moderate price 
increase.
PCN194
eStImatIoN of tHe treSHold PrICe of regorafeNIb IN tHe treatmeNt of 
uNreSeCtable aNd/or metaStatIC gaStroINteStINal Stromal tumorS 
after faIlure oN ImatINIb aNd SuNItINIb IN SPaIN: CoSt-utIlIty 
aNalySIS
Sanz-Granda Á1, Hidalgo-Figueruela F1, Granell M2
1Weber Economía y Salud, Majadahonda (Madrid), Spain, 2Bayer HealthCare, Sant Joan Despí ( 
Barcelona ), Spain
Objectives: To estimate the threshold price (TP) of regorafenib in Spain to be an 
efficient option in the treatment of unresectable and/or metastatic gastrointesti-
nal stromal tumors (GIST) that have progressed on imatinib and sunitinib, com-
pared with the best supportive care (BSC). MethOds: The TP is the maximum 
price at which regorafenib offers an efficient incremental cost-utility ratio (ICUR) 
in Spain (≤ 30,000 € /QALY). A probabilistic cost-utility Markov model of GIST treat-
ment was developed initially in Excel to estimate costs and benefits of regorafenib 
compared with the BSC, from a National Health System perspective, in a lifetime 
horizon. Efficacy (overall survival and progression-free survival) and utilities were 
extracted from the GRID study, and cost values (drugs, visits, monitoring, adverse 
events, and end-of-life costs), from Spanish databases and published data. Then, 
the TP was estimated by using the Solver Add-in and a cost utility analysis was 
performed. Results: The initial model estimated a total cost of 33,256 € (95CI: 
27,909-38,324), and utility of 1.718 QALY (95CI: 1,506-1,757) with regorafenib; the 
estimated values of BSC were 6,546 € (95CI: 5,637-7,026) and 1.073 QALY (95CI: 0.902-
1.112), respectively.The TP of regorafenib was estimated in 2.234 € , and the total 
cost was 25,901 € (95CI: 21,912-29,409), showing a difference compared to BSC of 
19,356 € (95CI: 16,431-21,376); the ICUR was 30,000 € /QALY (95CI: 25,556-35,795). 
The probability of cost-effectiveness with regorafenib was 51.8%, for a willingness 
to pay of 30,000 € /QALY. cOnclusiOns: Below an ex-factory price of 2.234€ , the 
treatment with regorafenib in unresectable and/or metastatic GIST whose disease 
has progressed on imatinib and sunitinib represents a cost effectiveness assigna-
tion of resources.
PCN195
tHe ComParatIVe PHarmaCoeCoNomIC aNalySIS of uSINg PlerIxafor 
for Stem Cell mobIlIzatIoN for autologouS PerIPHeral Stem Cell 
traNSPlaNtatIoN for NoN-HodgkIN’S lymPHoma PatIeNtS
Krysanova V1, Krysanov I2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2Postgraduate Medical 
Institute, Moscow National University of Food Production, Moscow, Russia
Objectives: Autologous peripheral stem cell transplantation (ASCT) with high-dose 
chemotherapy is a preferred treatment for non-Hodgkin’s lymphoma (NHL) patients. 
Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to 
G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The 
main aim of this study was to perform comparative pharmacoeconomic analysis of 
using G+P versus G-CSF as a method for SCM. MethOds: Analysis of the published 
clinical trials was conducted to evaluate comparative efficacy and safety of the 
studied therapy options. Taking into account the hypothesis of superior effective-
ness of combination G+P for SCM for pharmacoeconomic analysis was chosen 
“cost-utility” analysis. For this study was adopted a Markov model simulated the 
care process of NHL patients undergoing ASCT using data from the Washington 
University site of the plerixafor Phase III study (Kymes SM. et al, 2012). Direct medical 
costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ 
cell processing and cryopreservation. Mobilization and remobilization costs were 
defined to be the costs of medical procedures, resource utilization, and medica-
tions. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitiv-
ity analysis was made. Results: According to published trials the combination 
G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. 
Additionally, G+P mobilization resulted in more predictable days of collection, no 
weekend aphaeresis procedures, and no unscheduled hospital admissions. The 
expected lifetime cost of providing care for NHL patients using G+P was 601 294 
rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted 
life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitiv-
ity analysis showed that the results are more sensitive to the variations of key model 
parameter, such as price of plerixafor. cOnclusiOns: Using G+P for SCM in ASCT of 
patients with NHL was more effective and economically justified treatment option.
PCN196
effICIeNCy of exPeNSeS of gefItINIbum IN PatIeNtS WItH NoN-Small 
Cell luNg CaNCer aS a SeCoNd lINe tHeraPy
Rudakova AV1, Meshkov DO2, Khabriev RU2, Bezmelnitsyna LY2
1St. Petersburg Chemical-Pharmaceutical Academy, St. Petersburg, Russia, 2National Research 
Institution for Public Health, Moscow, Russia
Objectives: Therapy of non-small cell lung cancer is a very complex clinical prob-
lem. Revealing of an optimum version of therapy requires not only the analysis 
of data by clinical efficiency, but also assessments of efficiency of expenses for 
applied medical products. Objective of research was an assessment the efficiency 
of expenses of Gefitinibum in patients with non-small cell lung cancer as a second 
line therapy. MethOds: Modelling was made on the basis of results of clinical 
researches INTEREST. We considered only direct medical costs. Expenses for cor-
rection of the side effects cased hospitalization were counted on tariffs Compulsory 
Medical Service in St. Petersburg, 2013. Costs of compared medicines (Docetaxelum, 
Pemetrexed) were received from results of auctions for 01.08.2012-01.06.2013 (a 
database “Cursor”). Results: Data of the research had shown that in case of an 
inefficiency of chemotherapy of the first line therapy, Gefitinibum increased life 
expectancy in view of it’s quality on 0,013 QALY and provide savings the 276 USD for 
1 patient in comparison with original Docetaxelum. Costs for 1 month without pro-
Paquete A1, Miguel LS1, Pereira C2, Pinto CG3
1CISEP, Lisboa, Portugal, 2Roche Farmacêutica Bioquímica, Lda., Amadora, Portugal, 3University of 
Lisbon, Lisbon, Portugal
Objectives: To assess the incremental cost‐effectiveness ratio (ICER) of obinutu-
zumab in association with chlorambucil (GClb) for CLL previously untreated patients 
unsuitable for full-dose fludarabine based therapy, in the Portuguese National 
Health Service (NHS) perspective. Comparators are rituximab in association with 
chlorambucil (RClb) and chlorambucil alone (Clb). MethOds: A Markov model 
developed by Roche was used to predict disease progression and mortality, assum-
ing weekly cycles and a 25 years’ time horizon. Pre‐progression clinical data was 
based on CLL11 clinical trial (Goede et al.; 2015), and post‐progression data based 
on Eichhorst et al. (2009). Utility values were obtained on Kosmas et al. (2014). Only 
direct medical costs were included, being resource consumption estimated through 
a seven Portuguese experts panel and unit costs taken from official sources. A 5% 
discount rate was applied to both costs and consequences. Results: In comparison 
to RClb, GClb use allows an increase of 0.69 life years (LY) and of 0.66 quality adjusted 
life years (QALY) that are associated to an additional cost of 12,472€ . When compared 
to Clb, the use of GClb increases clinical gains by 1.07 LY and 0.99 QALYs at an addi-
tional cost of 24,104€ . Consequently, GClb costs 18,112€ per LY and 18,948€ per QALY 
in comparison to RClb and 22,447€ per LY and 24,352€ per QALY in comparison to 
Clb. Sensitivity analysis shows that results are mainly sensitive to the extrapolation 
methods of pre‐progression survival and to utility values. cOnclusiOns: The use 
of obinutuzumab in association with chlorambucil for CLL previously untreated 
patients that are unsuitable for full-dose fludarabine based therapy implies added 
costs per LY and per QALY that are generally accepted in Portugal. The cost‐effec-
tiveness ratios of obinutuzumab in association with chlorambucil (GClb) are below 
25,000€ when compared both to rituximab in association with chlorambucil (RClb) 
and to chlorambucil alone (Clb).
PCN192
CoSt-effeCtIVeNeSS of CetuxImab IN fIrSt-lINe treatmeNt of 
PatIeNtS WItH metaStatIC ColoreCtal CaNCer IN belgIum aNd tHe 
NetHerlaNdS
Krol M1, Ovcinnikova O2, von Hohnhorst P3, Jarrett J2
1Merck Serono, Schiphol-rijk, The Netherlands, 2Mapi, London, UK, 3Merck Serono, Frankfurt, 
Germany
Objectives: This study aimed to assess the cost-effectiveness of first-line treat-
ment of patients with cetuximab in combination with either FOLFOX or FOLFIRI 
with wild type rat sarcoma viral oncogene (RASwt) metastatic colorectal cancer 
in Belgium (B) and the Netherlands (NL) compared with treatment with FOLFOX 
or FOLFIRI. MethOds: A Markov model was developed to estimate the incremen-
tal cost-utility ratios (ICURs) of the following first-line treatment comparisons: 
cetuximab + FOLFIRI vs. FOLFIRI and cetuximab + FOLFOX vs. FOLFOX. The model 
was populated with trial data where possible. Only head-to-head trials were con-
sidered including cetuximab and RASwt data. Survival was estimated based on a 
disease modelling approach. Two versions of the model were created; one for NL 
and one for B. Country specific costs were included and second- and third-line 
treatments differed between NL and B. In line with the country’s health economic 
guidelines, analyses were conducted from a societal perspective (NL) or a health care 
perspective (B). Costs were discounted with 4% (NL) or 3% (B) and effects with 1.5%. 
The models adopted a 20 year time-horizon. A probabilistic sensitivity analysis 
was conducted to account for uncertainty. Results: The ICURs for NL and B were 
€ 86,180 and € 55,430 for cetuximab + FOLFIRI vs. FOLFIRI and € 83,151 and € 42,453 
for cetuximab + FOLFOX vs. FOLFOX. Uncertainty around the ICURs was relatively 
small in the FOLFIRI arms and considerable in the FOLFOX arms. cOnclusiOns: 
NL and B have no official ICUR thresholds, but unofficial upper limits are assumed 
to be around € 80,000 in NL and € 45,000 in B. ICURs were close to these limits. ICURs 
differed strongly between NL and B. This was mainly caused by lower drug costs in B.
PCN193
a CoSt-utIlIty aNalySIS of Nab-PaClItaxel (abraxaNe) PluS 
gemCItabINe IN metaStatIC PaNCreatIC CaNCer IN SloVak rePublIC
Stetka R1, Ondrusova M1, Psenkova M1, Pastorek T2, Salek T3
1Pharm-In Ltd, Bratislava, Slovak Republic, 2Celgene Ltd., Bratislava, Slovak Republic, 3Narodny 
onkologicky ustav, Bratislava, Slovak Republic
Objectives: Nab-paclitaxel is a solvent-free paclitaxel formulation approved for 
first-line treatment of patients with metastatic pancreatic cancer (MPC) in combi-
nation with gemcitabine. Treatment with nab-paclitaxel and gemcitabine has been 
shown to be clinically effective in an area of high unmet need. Patients treated 
with nab-paclitaxel and gemcitabine had an increase in median survival of 3.3 
months compared to those treated with gemcitabine alone in patient subgroup 
with Karnofsky Performance Score 70-80. MethOds: A Markov cohort model was 
constructed for patients with MPC to examine the costs and outcomes of nab-
paclitaxel and gemcitabine versus gemcitabine. Health outcomes were expressed 
in terms of life-years (LYs) and quality-adjusted life-years (QALYs) gained. Patient’s 
disease progression over time was modeled using data from the MPACT study. An 
area under the curve methodology was used to characterize patients’ disease status 
at different points in time. Parametric curves were fitted to the overall survival data, 
progression-free survival data and time on treatment data. Health Related Quality 
of Life data for each health state was sourced systematically from the literature. 
Resource unit costs and use were derived from local cross-sectional survey. The 
analysis was performed from payer’s perspective in Slovak settings. Results: The 
base case result was an incremental cost-effectiveness ratio (ICER) of € 27,769 per 
QALY gained for paclitaxel albumin plus gemcitabine versus gemcitabine, based on 
an incremental cost of € 5,943, incremental survival of 3.3 months and incremental 
QALYs of 0.214. The key driver of the incremental costs was the additional drug 
acquisition cost of adding nab-paclitaxel to gemcitabine. cOnclusiOns: € 28 820 
per QALY is defined as the upper limit for conditional reimbursement in Slovakia. 
Nab-paclitaxel and gemcitabine is the cost-effective option for the first-line treat-
